Sanofi and Regeneron have expanded their long-running immunology partnership, adding four next-generation antibody programs in a deal that could be worth as much as $8 billion to Regeneron.
Regeneron said it will receive $1 billion upfront and could earn up to another $7 billion tied to development, regulatory and commercial milestones. The companies will share development and commercialization costs equally, as well as any future profits.
Four long-acting antibody programs enter the alliance
The portfolio includes REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody, a long-acting IL-4xIL-13 bispecific antibody and two additional preclinical programs.
The partners have worked together for more than two decades and previously built the blockbuster immunology drug Dupixent. The new agreement extends that collaboration into treatments designed for less frequent dosing and broader immune-system targets.
Pipeline strategy comes into focus
For Sanofi, the transaction adds potential future products as the company prepares for eventual patent pressure on major medicines. Regeneron gains substantial upfront funding while retaining an equal economic role in the new programs.
The first candidate is already in Phase 1 testing, while additional programs are expected to enter clinical development in 2027. As with all early-stage drug programs, regulatory approval and commercial success are not guaranteed.
Sources: Regeneron and Sanofi joint announcement; Reuters, Oct. 1, 2026.
